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Purpose or Objective: The aim of this study was to compare 
treatment related side-effects and quality of life of an MRI-
based 95Gy boost to the multi-parametric MRI visible tumor 
with 77Gy whole prostate external beam radiotherapy in 
patients with intermediate or high risk localized prostate 
cancer. 
 
Material and Methods: FLAME (NCT01168479) was a phase 3, 
single blind, multi-center randomized controlled trial. 
Patients with biopsy proven intermediate and high risk 
prostate cancer (D’Amico risk classification) were randomly 
assigned and stratified per center. Analysis was done by 
intention to treat. The control group received a dose to the 
entire prostate of 77Gy in 35 fractions. The experimental arm 
received an additional integrated boost up to 95 Gy to the 
mp-MRI-visible lesions. Treatment related toxicity was 
measured by the Common Toxicity Criteria for adverse events 
version 3.0 (CTCAE). Quality of Life (QoL) was measured by 
SF-36, EORTC QLQ-C30 and EORTC QLQ-PR25. All items and 
scale scores were linearly transformed to a 0–100 scale, with 
higher scores reflecting either more symptoms or higher 
levels of functioning. Clinical relevance was considered a 
difference of more than 10 points between arms. Mean 
differences between groups were calculated using a linear 
mixed model with adjustment for baseline values. Statistical 
significance was considered P<0.01. 
 
Results: Between 2009 and 2015 287 patients were assigned 
to the control group and 284 to the dose-escalated (FLAME) 
arm. Mean follow up was 22 months. In both arms, 84% of 
patients had high risk disease. Regarding GU toxicity, 134 
patients (47.2%) in the FLAME arm and 147 patients (51.4%) in 
de control arm experienced any grade 2 or higher toxicity. 
Grade 3 GU toxicity occurred in 15 patients (5.3%) in the 
FLAME arm and 12 patients (4.2%) in the control arm. 
Regarding GI toxicity, 60 patients (21.1%) in the FLAME arm 
and 47 patients (16.4%) in the control arm experienced grade 
2 or higher toxicity. Grade 3 toxicity occurred in 2 patients 
(0.7%) in the FLAME arm and in 5 patients (1.7%) in the 
control arm. None of these differences were statistically 
significant. For all quality of life measures no statistically 
significant or clinical relevant differences were observed. 
 
 
Conclusion: Up to a median follow-up of 22 months no 
differences in toxicity and quality of life were observed 
between the FLAME arm and the standard arm. Therefore, 
dose escalated 95Gy MRI-based lesion boost in prostate 
cancer external beam radiotherapy seems safe. 
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Purpose or Objective: 'Watch and Wait' policy for complete 
clinical responders (cCR) following CRT is gaining acceptance 
as this avoids extirpative surgery and a stoma. However, up 
to 30% required major surgery for recurrences and organ 
preservation achieved reduced to 40% for the whole group. 
We report our experience with dose escalation using Contact 
X-ray brachytherapy [Papillon] (CXB) boost which reduce 
recurrences and improve the chance of organ preservation. 
 
Material and Methods: We review 573 patients with rectal 
cancer treated at Clatterbridge Cancer centre from 2003 -
2012 and report on 200 patients treated radically to cure by 
non-surgical approach. There were 134(67%) males with 
median age 74 years (range 32-94). Histological diagnosis 
confirmed in all patients. Staging include CT in all and MRI 
except in 30(15%) with pace maker. Radiological stages were 
21(10.5%) T1, 89(44.5%) T2, 87(43.5%) T3 and 3(1.5%) T4. 
EBCRT with 45 Gy /25#/35 days and capecitabine 825 mg/m 2 
or 5 FU infusion 1G /m 2 X 4 days week 1+5 was given to 127 
(63%)patients, except EBRT alone in unfit 57(28%) who had 25 
Gy/5#/5 days. Papillon boost of 80-110 Gy in 3-4 fraction was 
given to 92% of patients who had EBCRT or EBRT. Papillon 
alone (80-110 Gy /3-4 #/ 6 weeks) was used in 16 (8%) of 
elderly patients with mainly cT1 cancers. 
 
Results: Initial complete clinical response [cCR] (no residual 
tumor visible, palpable or on radiology) was achieved in 
